

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Sadoff J, Davis K, Douoguih M. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination — response from the manufacturer. *N Engl J Med*. DOI: 10.1056/NEJMc2106075

## Supplementary References

- S1. Greinacher A, Thiele T, Warkentin T, Weisser K, Kyrle P, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. *N Engl J Med* 2021;e-published ahead of print.
- S2. Schulz N, Sørvoll I, Michelsen A, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med* 2021;e-published ahead of print.
- S3. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. *N Engl J Med* 2021;e-published ahead of print.
- S4. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* 2020;396:467-78.
- S5. Bos R, Rutten L, van der Lubbe JEM, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. *NPJ Vaccines* 2020;5:91.